

# Robert C Read

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4453407/publications.pdf>

Version: 2024-02-01

49  
papers

3,658  
citations

257450

24  
h-index

189892

50  
g-index

53  
all docs

53  
docs citations

53  
times ranked

4766  
citing authors

#	ARTICLE	IF	CITATIONS
1	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. <i>European Respiratory Journal</i> , 2017, 50, 1700582.	6.7	792
2	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2258-2276.	13.7	519
3	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	13.7	430
4	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. <i>Nature Medicine</i> , 2022, 28, 1031-1041.	30.7	281
5	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. <i>Lancet, The</i> , 2014, 384, 2123-2131.	13.7	247
6	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	13.7	161
7	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 1131-1141.	9.1	99
8	Nasal Inoculation of the Commensal <i>Neisseria lactamica</i> Inhibits Carriage of <i>Neisseria meningitidis</i> by Young Adults: A Controlled Human Infection Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1512-1520.	5.8	95
9	Anti-adhesion methods as novel therapeutics for bacterial infections. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 1457-1468.	4.4	77
10	Nasopharyngeal Colonization by <i>Neisseria lactamica</i> and Induction of Protective Immunity against <i>Neisseria meningitidis</i> . <i>Clinical Infectious Diseases</i> , 2011, 52, 70-77.	5.8	70
11	PERISCOPE: road towards effective control of pertussis. <i>Lancet Infectious Diseases, The</i> , 2019, 19, e179-e186.	9.1	67
12	Phase I Safety and Immunogenicity Study of a Candidate Meningococcal Disease Vaccine Based on <i>Neisseria lactamica</i> Outer Membrane Vesicles. <i>Vaccine Journal</i> , 2009, 16, 1113-1120.	3.1	55
13	Reducing risks from coronavirus transmission in the home—the role of viral load. <i>BMJ, The</i> , 2020, 369, m1728.	6.0	48
14	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. <i>Journal of Infection</i> , 2022, 84, 795-813.	3.3	43
15	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. <i>ERJ Open Research</i> , 2018, 4, 00028-2018.	2.6	41
16	Controlled Human Infection With <i>Bordetella pertussis</i> Induces Asymptomatic, Immunizing Colonization. <i>Clinical Infectious Diseases</i> , 2020, 71, 403-411.	5.8	40
17	Professional challenges and opportunities in clinical microbiology and infectious diseases in Europe. <i>Lancet Infectious Diseases, The</i> , 2011, 11, 408-415.	9.1	38
18	Cooperative Role for Tetraspanins in Adhesin-Mediated Attachment of Bacterial Species to Human Epithelial Cells. <i>Infection and Immunity</i> , 2011, 79, 2241-2249.	2.2	38

#	ARTICLE	IF	CITATIONS
19	A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. <i>Vaccine</i> , 2017, 35, 427-434.	3.8	34
20	Haemophilus influenzae infection of Human Respiratory Mucosa in Low Concentrations of Antibiotics. <i>The American Review of Respiratory Disease</i> , 1993, 148, 201-207.	2.9	32
21	The environmental deposition of influenza virus from patients infected with influenza A(H1N1)pdm09: Implications for infection prevention and control. <i>Journal of Infection and Public Health</i> , 2016, 9, 278-288.	4.1	32
22	Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2021, 398, 1417-1426.	13.7	32
23	Malaria systems immunology: Plasmodium vivax induces tolerance during primary infection through dysregulation of neutrophils and dendritic cells. <i>Journal of Infection</i> , 2018, 77, 440-447.	3.3	29
24	Investigating <i>Bordetella pertussis</i> colonisation and immunity: protocol for an inpatient controlled human infection model. <i>BMJ Open</i> , 2017, 7, e018594.	1.9	26
25	Peptides from Tetraspanin CD9 Are Potent Inhibitors of Staphylococcus Aureus Adherence to Keratinocytes. <i>PLoS ONE</i> , 2016, 11, e0160387.	2.5	26
26	Neisserial Molecular Adaptations to the Nasopharyngeal Niche. <i>Advances in Microbial Physiology</i> , 2015, 66, 323-355.	2.4	24
27	Microevolution of Neisseria lactamica during nasopharyngeal colonisation induced by controlled human infection. <i>Nature Communications</i> , 2018, 9, 4753.	12.8	24
28	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 1049-1060.	10.7	24
29	The nonpathogenic commensal Neisseria: friends and foes in infectious disease. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 490-496.	3.1	21
30	<i>Neisseria meningitidis</i> serogroup B bivalent factor H binding protein vaccine. <i>Expert Review of Vaccines</i> , 2015, 14, 493-503.	4.4	18
31	Exploring the acceptability of controlled human infection with SARS-CoV-2: a public consultation. <i>BMC Medicine</i> , 2020, 18, 209.	5.5	18
32	Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases. <i>Journal of Immunology</i> , 2020, 205, 877-882.	0.8	17
33	Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation™, ready for rapid activation. <i>Health Technology Assessment</i> , 2015, 19, 1-78.	2.8	15
34	Kinetics of Immune Responses to Nasal Challenge With Meningococcal Polysaccharide One Year After Serogroup-C Glycoconjugate Vaccination. <i>Clinical Infectious Diseases</i> , 2011, 52, 1317-1323.	5.8	14
35	Neisseria meningitidis and meningococcal disease: recent discoveries and innovations. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 601-608.	3.1	13
36	A role for the tetraspanin proteins in Salmonella infection of human macrophages. <i>Journal of Infection</i> , 2017, 75, 115-124.	3.3	9

#	ARTICLE	IF	CITATIONS
37	Genomes of <i>Escherichia coli</i> bacteraemia isolates originating from urinary tract foci contain more virulence-associated genes than those from non-urinary foci and neutropaenic hosts. <i>Journal of Infection</i> , 2018, 77, 534-543.	3.3	9
38	A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	7
39	Analysis of histone post translational modifications in primary monocyte derived macrophages using reverse phase—reverse phase chromatography in conjunction with porous graphitic carbon stationary phase. <i>Journal of Chromatography A</i> , 2016, 1453, 43-53.	3.7	6
40	<i>Neisseria lactamica</i> Y92â€“1009 complete genome sequence. <i>Standards in Genomic Sciences</i> , 2017, 12, 41.	1.5	6
41	Protocol for a controlled human infection with genetically modified <i>Neisseria lactamica</i> expressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine. <i>BMJ Open</i> , 2019, 9, e026544.	1.9	6
42	The infant pharyngeal microbiomes: origin, impact and manipulation. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 548-555.	3.1	6
43	Modulation of Human Airway Barrier Functions during <i>Burkholderia thailandensis</i> and <i>Francisella tularensis</i> Infection. <i>Pathogens</i> , 2016, 5, 53.	2.8	5
44	Manipulating the infant respiratory microbiomes to improve clinical outcomes: A review of the literature. <i>Journal of Infection</i> , 2021, 82, 247-252.	3.3	4
45	A qPCR assay for <i>Bordetella pertussis</i> cells that enumerates both live and dead bacteria. <i>PLoS ONE</i> , 2020, 15, e0232334.	2.5	3
46	<i>Neisseria lactamica</i> Controlled Human Infection Model. <i>Methods in Molecular Biology</i> , 2022, 2414, 387-404.	0.9	3
47	Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study. <i>Wellcome Open Research</i> , 2022, 7, 49.	1.8	3
48	Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC-PC): the predictive value of molecular testing. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1238-1244.	6.0	3
49	Controlled human infection with <i>Neisseria lactamica</i> in late pregnancy to measure horizontal transmission and microbiome changes in motherâ€“neonate pairs: a single-arm interventional pilot study protocol. <i>BMJ Open</i> , 2022, 12, e056081.	1.9	3